| Bioactivity | P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease[1][2][3]. | |||||||||
| Invitro | P7C3 inhibits LPS-induced production of pro-inflammatory factors in BV2 cells[3].P7C3 markedly reduces the protein levels of iNOS and COX-2 in a dose-dependent manner without affecting the cell viability in the LPS (100 ng/mL)-stimulated BV2 cells[3].P7C3 inhibits LPS-induced nuclear translocation of NF-κB p65 subunit in BV2 cells[3].P7C3 suppresses LPS-induced degradation of inhibitory κB alpha (IκBα) by inhibiting IκB kinase (IKK) activation[3]. Western Blot Analysis[3] Cell Line: | |||||||||
| In Vivo | P7C3 (20 mg/kg/d; i.p.; twice daily; for 21 days ) inhibits microglial activation and microglia-mediated dopaminergic (DA) neuronal loss in vivo[3]. Animal Model: | |||||||||
| Name | P7C3 | |||||||||
| CAS | 301353-96-8 | |||||||||
| Formula | C21H18Br2N2O | |||||||||
| Molar Mass | 474.19 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Pieper AA et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010 Jul 9;142(1):39-51. [2]. Pieper AA et al. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev. 2014 Oct 7;43(19):6716-26. [3]. Chao Gu , et al. P7C3 Inhibits LPS-Induced Microglial Activation to Protect Dopaminergic Neurons Against Inflammatory Factor-Induced Cell Death in vitro and in vivo. Front Cell Neurosci. 2018; 12: 400. [4]. Blaya MO, Wasserman JM, Pieper AA, Sick TJ, Bramlett HM, Dietrich WD. Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. Neuropharmacology. 2019;145(Pt B):268-282. |